Exposure –response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

ConclusionsOverall survival of metastasized melanoma patients with trametinib Cmin levels  ≥ 15.6 ng/mL is ten months longer compared to patients with Cmin below this threshold. This would theoretically provide a rationale for therapeutic drug monitoring of trametinib. Although a high proportion of patients are underexposed, there is very little scope for dose increments due to the risk of serious toxicity.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research